The National Organization for Rare Diseases (NORD)
® - The Physicians Guide To Hereditary Angioedema
- 1. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema. Arch Intern Med. 2001;161:2417-2429.
- 2. Bork K, Siedlecki K, Bosch S, et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc. 2000;75: 349-354.
- 3. Hereditary angioedema: pathophysiology and new treatments in development. [in press] Lev Pharmaceuticals.
- 4. Davis AE. The pathophysiology of hereditary angioedema. Clin Immunol. 2005;114: 3-9.
- 5. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol. 2005;139: 379-394.
- 6. Moore GP, Hurley WT, Pace SA. Hereditary angioedema. Ann Emerg Med. 1998;17: 1082-1086.
- 7. Jensen NF, Weiler JM. C1 esterase inhibitor deficiency, airway compromise, and anesthesia. Anesth Analg. 1998;87:480-488.
- 8. Gompels MM, Lock RJ, Morgan JE, et al. A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency. J Clin Pathol. 2002;55:145-147.
- 9. Zuraw BL. Current and future therapy for hereditary angioedema. Clin Immunol. 2005;114: 10-16.
- 10. Danocrine (Danazol) [package insert]. New York, NY: Marketed by Sanofi-Synthelabo Inc.; October 2006.
- 11. Hosea SW, Frank MM. Danazol in the treatment of hereditary angioedema. Drugs.1980;19: 370-372.
- 13. Zurlo JJ, Frank MM. The long-tem safety of danazol in women with hereditary angioedema. Fertil Steril. 1990;54: 64-72.
- 14. Weiler CR, Van Dellen RG. Genetic test indications and interpretations in patients with hereditary angioedema. Mayo Clin Proc. 2006;81(7): 958-972.